Praxis Precision Medicines, Inc. PRAX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s financing cash flow?
- Praxis Precision Medicines, Inc. (PRAX) reported financing cash flow of $609.43M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s financing cash flow changed year-over-year?
- Praxis Precision Medicines, Inc.'s financing cash flow increased by 1023.0% year-over-year, from $54.27M to $609.43M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s financing cash flow has grown at a 59.8% compound annual growth rate (CAGR), from $107.59M to $702.17M.
- What does financing cash flow mean?
- The net cash flow from raising capital or paying down debt.
- How do you interpret financing cash flow?
- Positive values indicate the company is raising capital, while negative values indicate debt repayment or share buybacks.
- How does financing cash flow compare across companies?
- Typically positive for clinical-stage companies that rely on equity financing to fund operations.